Editorial status: Evidence-informed draft for clinician review. Graft need, material and timing depend on the defect, patient, surgical plan and local regulation.

“Bone graft” describes a goal, not one material

Dental grafting may preserve an extraction socket, widen a ridge, rebuild a vertical defect or support sinus augmentation. The material can come from the patient, a human donor, an animal source, a synthetic product or a mixture. Membranes, fixation devices and blood-derived products may be used alongside it. Consent should identify each planned component.

Start with the defect and restorative endpoint

A graft should address a measured anatomical and prosthetic need. Ask which implant position, ridge contour or tissue support cannot be achieved predictably without augmentation. The surgeon should explain defect dimensions, soft tissue, infection, sinus anatomy and how the final restoration drives the plan.

Not every implant site needs grafting

Alternative implant position, narrower or shorter implants, staged treatment, a bridge, removable prosthesis or no replacement may avoid grafting in selected cases. Some sinus-elevation protocols have evidence without graft material. An alternative may trade bone gain for other limitations; it should still be discussed before consent.

Autogenous graft

Autogenous material comes from the same patient, often from an intraoral donor site and sometimes another anatomical site. It can provide living cells and a natural scaffold but creates donor-site surgery, morbidity and limited volume. Record donor site, harvest method, fixation and whether it is mixed with another material.

Allograft

Allograft is processed human donor tissue. Products differ in source, processing, mineral content, particle form and intended use. Explain tissue-bank controls, screening, processing and residual risks in understandable terms. Record manufacturer, exact product, lot, expiry and regulatory documentation supplied with the case.

Xenograft

Xenograft is derived from another species, commonly bovine or porcine sources after processing. It may act as a slowly resorbing scaffold. Patients may have religious, ethical, allergy or personal concerns about animal origin. “Natural bone” is not sufficient disclosure; name the species and product.

Alloplast

Alloplast is a synthetic graft substitute, such as calcium phosphate-based materials, with properties that vary by chemistry, porosity and resorption. Synthetic does not mean universally safer or equally effective for every defect. The surgeon should match the product’s indication and handling to the clinical need.

Tooth-derived graft

Processed autogenous or donor tooth material has been studied in selected augmentation settings. Evidence is still developing and protocols vary. Consent should explain whether the patient’s own extracted tooth is processed, where processing occurs, what other material is mixed and what alternatives have stronger evidence.

Composite grafts

Surgeons may combine autogenous chips with a slower-resorbing substitute or other products. A mixture can balance handling and biological goals, but the patient should receive the identity and approximate role of every component. One label should not obscure several implanted materials.

Membranes

Guided bone regeneration often uses a resorbable or non-resorbable membrane to exclude soft tissue and maintain space. Record material, animal or synthetic origin, product, fixation and whether removal is expected. Membrane exposure can alter care and may require additional treatment.

Titanium mesh and fixation

Meshes, screws, pins or plates may maintain space or secure blocks. Consent should state whether they are temporary or intended to remain, how removal is decided and what happens if exposed. Record dimensions, manufacturer and location so future imaging and surgery can be interpreted accurately.

PRF, CGF and blood-derived adjuncts

Platelet-rich fibrin or concentrated growth factors are prepared from the patient’s blood and may be used alone or with graft material. Evidence varies by procedure and preparation protocol. These products should not be marketed as guaranteed regeneration. Record blood draw, preparation system and clinical role.

Biologics and growth factors

Some products contain recombinant factors or biologically active agents with specific indications, contraindications and costs. They are not interchangeable with routine graft particles. Consent should name the active product, regulatory indication, off-label use where applicable and known risks.

Sinus augmentation choices

Sinus elevation can use lateral or transcrestal approaches, with or without graft material in selected cases. Reviews report high implant survival in both grafted and graftless groups but differences in bone gain and evidence quality. Residual bone, membrane integrity, implant stability and anatomy influence selection.

Socket preservation

Socket grafting aims to reduce ridge dimensional change after extraction; it does not preserve the socket unchanged or guarantee later implant placement without further grafting. The plan should identify whether immediate implant placement is intended, what tissue closure is needed and when reassessment occurs.

Horizontal ridge augmentation

Horizontal defects may be treated with particulate graft and membrane, block graft, ridge split or other strategies. Each has different space-maintenance, healing and complication profiles. The surgeon should explain expected gain as a range and what would trigger a second procedure.

Vertical augmentation

Vertical bone gain is technically demanding and can have greater exposure or graft-loss consequences. Consent should include the possibility of incomplete gain, staged implant placement, device removal and altered prosthetic design. A marketed millimetre target is not a guaranteed outcome.

Infection and site preparation

Active infection, poor plaque control, smoking and uncontrolled disease can affect healing. Source control and tissue management may need to precede augmentation. Antibiotics do not convert an unsuitable site into a predictable graft. Document preoperative findings and the reason for timing.

Medical and medication review

Diabetes, immune conditions, previous radiation, antiresorptive or antiangiogenic medicines, anticoagulants, allergies and other factors can change risk. Do not stop prescribed medicine without coordination. The surgeon may need medical advice and should record the shared plan.

Smoking and nicotine

Smoking and nicotine exposure can impair wound healing and increase complication risk. Ask about cigarettes, vaping and other nicotine products. Give a realistic cessation plan and document how continued use affects prognosis, rather than hiding the issue in a general instruction sheet.

Material-source consent

Before surgery, the patient should know whether material is self-derived, human donor, bovine, porcine, synthetic or mixed. Discuss personal or religious concerns without judgment and offer clinically reasonable alternatives. Consent obtained after sedation or after the material is opened is too late.

Traceability record

For every implanted product, record manufacturer, commercial name, catalogue or reference number, lot or batch, expiry, quantity when available, site and date. Keep the original label or a verified electronic copy linked to the patient. This supports recalls, adverse-event reporting and later surgery.

Cold chain and storage

Some products have specific storage, transport and preparation requirements. The clinic should follow the manufacturer’s validated instructions and document deviations. A sealed package alone does not prove correct storage. Patients need not audit a refrigerator, but they may request product identity and traceability.

Sterility and packaging

Verify packaging integrity, expiry and intended single use before opening. Record who prepared the field and product. Do not use a product with damaged packaging or uncertain identity. Mixing containers and syringes should preserve traceability throughout the procedure.

Off-label and modified use

A clinician may consider a product outside its labelled indication based on judgement and evidence. That decision should be disclosed where material, including rationale, alternatives and uncertainty. Marketing claims or custom mixing do not replace informed consent and documentation.

Quantity and location

Record which material was placed at each site, particularly when several defects or bilateral sinus procedures use different products. Approximate volume or package quantity can be useful. A discharge note saying “bone graft placed” is inadequate for later interpretation.

Healing does not equal replacement by living bone

Graft particles can resorb slowly or remain visible radiographically. Histological composition differs by material and time. A dense image does not automatically mean strong vital bone, and absence of visible particles does not prove failure. Clinical decisions integrate healing time, imaging, stability and surgical findings.

Imaging follow-up

Use imaging only when justified by the clinical question. Compare with preoperative and immediate postoperative records using appropriate technique. CBCT can show volume and anatomy but cannot alone prove histological quality or osseointegration. The report should identify incidental findings and limitations.

Healing time

Healing depends on defect, material, fixation, vascular supply, patient factors and implant timing. Give a range and criteria for progression rather than a guaranteed month. Early exposure, infection or incomplete gain can lengthen treatment or change the restorative plan.

Expected postoperative course

Provide procedure-specific instructions for swelling, bruising, bleeding, diet, hygiene and medicines. Explain sinus precautions where relevant. The patient should know who to contact after hours and which symptoms require emergency medical care versus urgent dental review.

Complications

Possible events include pain, swelling, infection, membrane exposure, wound opening, graft loss, donor-site symptoms, sinus complications, nerve disturbance, bleeding and failure to gain sufficient bone. Additional surgery, altered implant position or an alternative prosthesis may be required. Percentages should match the actual technique where possible.

What graft “success” means

Success can mean wound closure, maintained volume, histological bone, ability to place an implant, implant survival or patient satisfaction. These are not identical. Ask what outcome supports the clinic’s quoted success rate, at what time and with what follow-up completeness.

Graft failure and remedial planning

If exposure or infection occurs, document timing, material, culture or findings, treatment and remaining anatomy. Removal, partial salvage, re-grafting or a non-graft alternative may be considered. Repeating the same technique without identifying the cause can repeat failure.

Cross-border continuity

Patients treated abroad should return with operative notes, material labels, imaging and aftercare contacts. A local surgeon needs to know what was placed before managing exposure, infection or later implant surgery. Warranty approval must not delay urgent care.

Cost transparency

The quotation should separate surgical work, donor-site surgery, graft products, membranes, fixation, biologics, imaging, sedation, removal procedures and possible re-grafting. “Premium graft” is not a clinical specification. Product cost alone does not establish superiority.

Questions before consent

What defect is being treated and what is the restorative goal?
Can treatment proceed without grafting?
What is the exact source and product?
Which membrane, fixation or biologic will be used?
Is any use off-label?
What healing criteria determine implant placement or loading?
What happens if the expected bone gain is not achieved?

Patient graft passport

Procedure, site and date.
Surgeon and clinic.
Autogenous donor site where used.
Every product name, source, manufacturer and lot.
Membrane and fixation details.
Biologic or blood-derived adjunct.
Baseline and follow-up imaging.
Complications, removals and future maintenance plan.

Histology and biopsy

Some staged cases allow a small core sample at implant preparation, but biopsy is not routine for every graft and has its own purpose and limitations. If histology is performed, retain the report and site. Marketing images from another patient do not prove the composition or maturity of an individual graft.

Product recall readiness

Traceability allows a clinic to identify patients if a manufacturer or regulator issues a notice. The clinic should maintain a process to link lot numbers to sites and contact details. Patients should keep their graft passport but should not be made solely responsible for recall records.

Adverse-event reporting

Unexpected infection, reaction, packaging defect or device failure may need reporting to the manufacturer or relevant authority. Record product identity, timing, clinical findings and treatment without assuming causation. Transparent reporting improves surveillance and preserves information for other clinicians.

Substitution on the day of surgery

If the planned product is unavailable or the defect differs from imaging, the surgeon may consider another material or technique. Where urgency allows, pause and explain the source, evidence, risks, cost and alternatives. Broad consent to “any graft” is not meaningful authorisation for an undisclosed human or animal product.

Residual material at later surgery

A future clinician may encounter persistent particles, membrane, mesh or fixation screws. The operative record should make these findings expected rather than mysterious. Removal is not automatically required; the decision depends on symptoms, infection, implant plan, tissue integration and the specific device.

Evidence summary

Dental graft materials differ in source, processing, persistence and evidence. Some augmentation goals can be met without graft material in selected cases. Safe consent links the material to a measured defect, discloses human or animal origin and alternatives, and preserves exact product and lot traceability for future care.

Sources

Prepared as general educational information. Graft selection and consent require examination and a procedure-specific discussion with the surgeon.

Dental Bone Graft Materials, Traceability and Consent